AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
20.2 C
New York
Tuesday, October 20, 2026

Tag: percentage

newsFORsourcecompanycontentinformation1releasesmarket

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Communiqué Orange : Orange signs a joint agreement to acquire SFR, a decisive step that will reinforce its leadership in France

Press release
Paris, 6 June 2026

Perpetua Resources Reports Results of 2026 Annual Meeting

BOISE, Idaho, June 5, 2026 /CNW/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or "Perpetua" or the "Company") today announced the...

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026 

STEALTHGAS INC. Reports First Quarter 2026 Financial And Operating Results

ATHENS, Greece, June 05, 2026 (GLOBE NEWSWIRE) -- STEALTHGAS INC. (NASDAQ: GASS), a ship-owning company serving the liquefied petroleum gas (LPG) sector of the international shipping industry, announced today its unaudited financial and operating results for the first quarter ended March 31, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPercentage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers